Purpose and methods: Bone and soft tissue sarcomas currently comprise 1% of adult malignancies and 15% of pediatric malignancies [1]. While doxorubicin and ifosfamide are active agents, no significant impact on survival has been observed. More active regimes are required in sarcoma. This trial studied cisplatin and a 5 day continuous infusion of vinblastine for patients who had had disease progression of advanced soft tissue sarcoma after a doxorubicin based regimen.
Results: Between July 1983 and October 1986, 20 patients entered the study. There were no treatment related deaths. Seven patients required dose adjustment for neutropenia. No responses were observed.